首页> 外文期刊>International Journal of Clinical Pharmacology Research >Lack of antagonism between nicorandil and sulfonylurea in stable angina pectoris.
【24h】

Lack of antagonism between nicorandil and sulfonylurea in stable angina pectoris.

机译:稳定心绞痛中尼可地尔和磺酰脲之间缺乏拮抗作用。

获取原文
获取原文并翻译 | 示例
       

摘要

The aim of this study was to clarify whether or not nicorandil (a potassium channel opener) caused adverse reactions in patients with angina pectoris who also had diabetes mellitus treated with sulfonylurea (a potassium channel inhibitor). Nineteen diabetic patients with angina pectoris were enrolled, eight were treated with glibenclamide (group A) and 11 were not (group B). Treadmill exercise testing and frequency of anginal attacks were used to evaluate the severity of angina pectoris. Blood sugar and hemoglobin A1c were measured for evaluation of diabetes mellitus control. Exercise tolerance, frequency of anginal attacks and diabetes mellitus control were not perturbed by treatment in either group. In conclusion, there were no antagonistic reactions from the combination of nicorandil with sulfonylurea in angina pectoris complicated by diabetes mellitus.
机译:这项研究的目的是弄清尼可地尔(钾通道开放剂)是否对患有心绞痛的心绞痛患者也引起了磺脲类药物(钾通道抑制剂)治疗的糖尿病产生不良反应。纳入19例患有心绞痛的糖尿病患者,其中8例接受格列本脲治疗(A组),另11例未接受治疗(B组)。跑步机运动测试和心绞痛发作频率用于评估心绞痛的严重程度。测量血糖和血红蛋白A1c以评估糖尿病对照。两组的运动耐受性,心绞痛发作频率和糖尿病控制均不受治疗干扰。总之,尼可地尔与磺酰脲类药物联合治疗心绞痛并发糖尿病无拮抗反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号